IMMPF / Immupharma's US partner confirms support for lupus treatment and wants to expand collaboration

ImmuPharma has raised £1.35 million through subscriptions for new equity that the biotech said will give it a cash runway until at least the end of more_horizontal

ImmuPharma PLC (AIM:IMM, OTC:IMMPF), a clinical-stage biopharmaceutical company, is on the cusp of a major breakthrough in the development of a new l more_horizontal

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) is set to initiate a Phase 2/3 adaptive clinical trial for its P140 (Lupuzor) drug in systemic lupus erythematosus more_horizontal

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) shares leapt 6.5% in late morning trading following encouraging news on its experimental drug P140. The US Food a more_horizontal

ImmuPharma PLC (AIM:IMM, OTC:IMMPF), a specialist drug discovery and development firm, has announced significant progress with its late-stage clinical more_horizontal

ImmuPharama PLC's focus for the current year will be on moving Lupuzor, its treatment for the autoimmune disease lupus, into a phase II/III clinical t more_horizontal

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has confirmed a Type-C meeting is scheduled with the US Food & Drug Administration for June 7. Scientists will di more_horizontal

Shares of ImmuPharma PLC (AIM:IMM, OTC:IMMPF) rose 4% to 2.33p following news of progress in the development of a second indication for its lead asset more_horizontal